Lilly's Donanemab Faces NHS Ban Over Cost
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's Alzheimer's drug, Donanemab, faces a potential ban by the NHS due to its high cost, despite being considered highly effective.
October 22, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's Alzheimer's drug, Donanemab, is at risk of being banned by the NHS due to its high cost, despite its effectiveness. This could impact Eli Lilly's revenue from the UK market.
The NHS's potential ban on Donanemab due to cost concerns could limit Eli Lilly's market access in the UK, affecting its revenue from this region. The drug's effectiveness is acknowledged, but the cost issue poses a significant barrier.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90